Shares in Telix Pharmaceuticals have jumped following positive safety data from its TLX591 trial. According to Citi analyst Laura Sutcliffe, the data removes a key overhang for the shares and boosts confidence that the second part of the ProstACT Global trial will proceed as planned in the United States. Telix Pharmaceuticals is a biopharmaceutical company focused on developing diagnostic and therapeutic products using molecularly targeted radiation.
Sutcliffe noted that grade 3 and grade 4 adverse events were broadly split across the three treatment groups, which combined TLX591 with sequential docetaxel, abiraterone, and enzalutamide. This distribution suggests the overall safety profile still allows for subsequent chemotherapy, a crucial factor for the trial’s progression.
The analyst’s assessment reduces the likelihood of the docetaxel arm being removed from the second stage of the trial. Citi continues to assume that all three treatment combinations will move forward following discussions with the US Food and Drug Administration. The positive sentiment surrounding the trial’s prospects has clearly resonated with investors, driving up the company’s share price.
In afternoon trading, Telix shares were up 6.9 per cent, reflecting the market’s positive reaction to the safety data and the anticipated progress of the ProstACT Global trial. Investors are watching closely as Telix moves forward with its clinical development program.
